FuXiang Medical Invites You to the 7th Future Healthcare 100 Summit 2023
Over the past decade, the global healthcare industry has undergone significant restructuring, a transformation accelerated by the COVID-19 pandemic since 2020. Having withstood the compounded challenges of global upheavals and the century-defining pandemic from 2020 to 2022, 2023 marked the first year for implementing the strategic directives laid out at the 20th National Congress of the Communist Party of China, as well as a critical year for advancing the 14th Five-Year Plan. Only by accumulating strength, demonstrating the resilience to “remain steadfast despite countless trials,” and embodying the spirit to “press forward in the face of greater difficulties,” can innovators in the healthcare sector reinforce their confidence through decisive action and successfully deliver on the era’s mandate for high-quality development in healthcare.
The 7th Future Healthcare Top 100 Conference, themed “No Boundaries Between East and West,” was hosted by VCBeat VB100 and Eggshell Research Institute, with strategic cooperation from Shanghai Zhangjiang Group. Integrating “cutting-edge academic and research insights, comprehensive industry perspectives, and keen awareness of capital trends,” the event took place from May 5 to 7, 2023, at the Shanghai Zhangjiang Science Hall. Together with industry peers, it explored the innovative future of the broader health sector, embarking on a new journey in healthcare innovation.
After six editions, the conference has become China’s largest and most information-rich ecosystem summit for the integration of industry and capital in the healthcare innovation sector. Centered on “connecting global wisdom, sharing cutting-edge technologies, inspiring the technological future, and focusing on venture capital interaction,” it sets the trend for innovation and investment in China’s healthcare field. The 7th Future Healthcare Top 100 Conference in 2023 will feature three major summits, over 20 thematic forums in specialized fields, the release of the Future Healthcare Top 100 series rankings and awards, more than 10 series reports, and seven concurrent networking events. It will bring together a diverse array of guests and attendees, including government agencies, academicians and scientists, clinical and research experts, Fortune 500/listed companies, top-tier investment institutions and securities firms, and innovative healthcare enterprises. Through this gathering of minds, the conference aims to provide insights to the industry and usher in a new future.
As global population aging continues to intensify, traditional therapeutic models struggle to address numerous challenges related to the repair and regeneration of tissue and organ defects. Regenerative medicine holds significant strategic importance by creating functional living cells, tissues, or organs to repair or replace those damaged by aging, disease, or injury. Consequently, it has become a major focus of long-term policy encouragement in various countries and attention from leading institutions.
In recent years, research in tissue regeneration and related fields has been gaining momentum, with many universities, hospitals, research institutions, and enterprises already entering this domain. Nevertheless, it is certain that the field of regenerative medicine still holds immense untapped potential. Where lies the next “new door” for industrial innovation and development? How can it be opened? These are the future challenges that the industry must collectively address.
Silk fibroin has gradually emerged as a standout among various biomaterials due to its superior bioactivity. As a representative example of novel biomaterials, silk fibroin is widely applied in fields such as tissue engineering, regenerative medicine, medical aesthetics, and nutritional medicine, garnering significant enthusiasm from both investors and the market.
At the Future Healthcare Top 100 Conference, Liu Yezhuo, Founder and CEO of Fuxiang Medical, will attend the Forum on Innovative Development in Regenerative Medicine and participate in a roundtable discussion. He will deliver a keynote speech on the innovative applications of silk fibroin, engaging with industry experts and leaders to explore critical issues such as relevant policies, technologies, products, and development prospects.
“Fuxiang Medical” was established in 2020, dedicated to innovative product development based on scientific research achievements in silk fibroin materials, leading the transformation of biomaterials for tissue repair engineering. The company boasts a 2,000-square-meter R&D center and production-grade cleanroom facilities, equipped with industry-leading instruments such as Atomic Force Microscopes (AFM), 3D printing systems, and superhydrophobic equipment.
Fuxiang Medical’s core team comprises master’s and doctoral graduates from Fudan University’s Biomacromolecules Research Group, along with numerous professionals from the medical device industry. The team has established extensive, in-depth collaborative partnerships with several renowned Grade IIIA hospitals, including Zhongshan Hospital, Huashan Hospital, Shanghai Ninth People’s Hospital, Shanghai Sixth People’s Hospital, and Changhai Hospital, all affiliated with Fudan University or based in Shanghai.
In the innovative field of "silk fibroin" materials, Fuxiang Medical has developed silk fibroin-based products in various forms, including consumables such as absorbable interference screws, biodegradable and absorbable silk fibroin bone anchors, and 3D-printed cartilage, as well as products like biological patches and skin wound repair membranes (also known as "artificial skin").
Currently, mature products such as “Soluble Silk Fibroin Powder SFMAGIC” have been launched and are commercially available, with primary applications in scientific research, healthcare, medical aesthetics, and daily chemical industries.
Silk fibroin bone nails (“SILKNAIL”) and artificial ligaments (“SILKLIGA”) for sports medicine surgery have completed animal studies and are poised to initiate clinical trials. These products are suitable for metaphyseal fractures at joint sites, fixation of bone grafts in revision arthroplasty, ligament reconstruction for sports injuries, and fixation of bone block grafts in defects following bone tumor resection. They exhibit closer similarity to human bone and superior biocompatibility.
In terms of storage and transportation, Fuxiang Medical has developed an innovative process to convert silk fibroin solution into a powder form characterized by high molecular weight, high stability, high consistency, and controllable molecular weight distribution. This advancement facilitates storage and transportation, resolves logistical challenges, and enables the industrialized, large-scale development of this novel material.
